Hepatocyte-targeted MR contrast agents: Contrast enhanced detection of liver cancer in diffusely damaged liver

Akihiro Tanimoto, Sachio Kuribayashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The performance of hepatocyte-targeted magnetic resonance (MR) contrast agents in the detection of liver tumor was tested in rats with hepatitis. Hepatocyte-targeted MR contrast agents (paramagnetic hepatobiliary complex [manganese-DPDP] and superparamagnetic iron oxide coated with arabinogalactan [SPIO-AG]) were injected into normal rats and rats with carbon tetrachloride-induced hepatitis. Before and after injection of either contrast agent, ex vivo relaxometry (0.94T) or in vivo MR imaging (1.0T) were performed. The obtained liver and tumor T1 and T2 relaxation times, liver and tumor signal-to-noise ratios (SNR), and tumor-liver contrast-to-noise ratios (CNR) of control rats and rats with hepatitis were compared. Both relaxometry and MR imaging showed that MnDPDP and SPIO-AG selectively enhanced liver tissue in controls and in rats with hepatitis to the same degree, and little tumor enhancement was seen in either group. As a result, no significant difference between control rats and rats with hepatitis was observed in the postcontrast tumor-liver CNR. For a MnDPDP-enhanced CNR with spin echo (SE) of 310/15, the results were -10.4±3.6 in control rats vs. -11.5±1.4 in rats with hepatitis; for a SPIO-AG-enhanced CNR with SE 2000/45 and 2000/90, respectively, the results were 30.7±9.2 and 18.7±4.7 in control rats vs. 31.9±7.1 and 17.7±2.4 in rats with hepatitis. These results indicate that hepatocyte-targeted contrast agents effectively enhance liver tissue and enhance liver-tumor image contrast despite hepatocellular dysfunction.

Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalMagnetic Resonance in Medical Sciences
Volume4
Issue number2
DOIs
Publication statusPublished - 2005

Fingerprint

Liver Neoplasms
Contrast Media
Hepatocytes
Magnetic Resonance Spectroscopy
Liver
Hepatitis
Noise
Neoplasms
Magnetic Resonance Imaging
Carbon Tetrachloride
Signal-To-Noise Ratio

Keywords

  • Contrast media
  • Hepatitis
  • Iron
  • Liver neoplasms
  • Manganese

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Hepatocyte-targeted MR contrast agents : Contrast enhanced detection of liver cancer in diffusely damaged liver. / Tanimoto, Akihiro; Kuribayashi, Sachio.

In: Magnetic Resonance in Medical Sciences, Vol. 4, No. 2, 2005, p. 53-60.

Research output: Contribution to journalArticle

@article{f8f3e720ae2940d7927a685f075ee484,
title = "Hepatocyte-targeted MR contrast agents: Contrast enhanced detection of liver cancer in diffusely damaged liver",
abstract = "The performance of hepatocyte-targeted magnetic resonance (MR) contrast agents in the detection of liver tumor was tested in rats with hepatitis. Hepatocyte-targeted MR contrast agents (paramagnetic hepatobiliary complex [manganese-DPDP] and superparamagnetic iron oxide coated with arabinogalactan [SPIO-AG]) were injected into normal rats and rats with carbon tetrachloride-induced hepatitis. Before and after injection of either contrast agent, ex vivo relaxometry (0.94T) or in vivo MR imaging (1.0T) were performed. The obtained liver and tumor T1 and T2 relaxation times, liver and tumor signal-to-noise ratios (SNR), and tumor-liver contrast-to-noise ratios (CNR) of control rats and rats with hepatitis were compared. Both relaxometry and MR imaging showed that MnDPDP and SPIO-AG selectively enhanced liver tissue in controls and in rats with hepatitis to the same degree, and little tumor enhancement was seen in either group. As a result, no significant difference between control rats and rats with hepatitis was observed in the postcontrast tumor-liver CNR. For a MnDPDP-enhanced CNR with spin echo (SE) of 310/15, the results were -10.4±3.6 in control rats vs. -11.5±1.4 in rats with hepatitis; for a SPIO-AG-enhanced CNR with SE 2000/45 and 2000/90, respectively, the results were 30.7±9.2 and 18.7±4.7 in control rats vs. 31.9±7.1 and 17.7±2.4 in rats with hepatitis. These results indicate that hepatocyte-targeted contrast agents effectively enhance liver tissue and enhance liver-tumor image contrast despite hepatocellular dysfunction.",
keywords = "Contrast media, Hepatitis, Iron, Liver neoplasms, Manganese",
author = "Akihiro Tanimoto and Sachio Kuribayashi",
year = "2005",
doi = "10.2463/mrms.4.53",
language = "English",
volume = "4",
pages = "53--60",
journal = "Magnetic Resonance in Medical Sciences",
issn = "1347-3182",
publisher = "Japan Society of Magnetic Resonance in Medicine",
number = "2",

}

TY - JOUR

T1 - Hepatocyte-targeted MR contrast agents

T2 - Contrast enhanced detection of liver cancer in diffusely damaged liver

AU - Tanimoto, Akihiro

AU - Kuribayashi, Sachio

PY - 2005

Y1 - 2005

N2 - The performance of hepatocyte-targeted magnetic resonance (MR) contrast agents in the detection of liver tumor was tested in rats with hepatitis. Hepatocyte-targeted MR contrast agents (paramagnetic hepatobiliary complex [manganese-DPDP] and superparamagnetic iron oxide coated with arabinogalactan [SPIO-AG]) were injected into normal rats and rats with carbon tetrachloride-induced hepatitis. Before and after injection of either contrast agent, ex vivo relaxometry (0.94T) or in vivo MR imaging (1.0T) were performed. The obtained liver and tumor T1 and T2 relaxation times, liver and tumor signal-to-noise ratios (SNR), and tumor-liver contrast-to-noise ratios (CNR) of control rats and rats with hepatitis were compared. Both relaxometry and MR imaging showed that MnDPDP and SPIO-AG selectively enhanced liver tissue in controls and in rats with hepatitis to the same degree, and little tumor enhancement was seen in either group. As a result, no significant difference between control rats and rats with hepatitis was observed in the postcontrast tumor-liver CNR. For a MnDPDP-enhanced CNR with spin echo (SE) of 310/15, the results were -10.4±3.6 in control rats vs. -11.5±1.4 in rats with hepatitis; for a SPIO-AG-enhanced CNR with SE 2000/45 and 2000/90, respectively, the results were 30.7±9.2 and 18.7±4.7 in control rats vs. 31.9±7.1 and 17.7±2.4 in rats with hepatitis. These results indicate that hepatocyte-targeted contrast agents effectively enhance liver tissue and enhance liver-tumor image contrast despite hepatocellular dysfunction.

AB - The performance of hepatocyte-targeted magnetic resonance (MR) contrast agents in the detection of liver tumor was tested in rats with hepatitis. Hepatocyte-targeted MR contrast agents (paramagnetic hepatobiliary complex [manganese-DPDP] and superparamagnetic iron oxide coated with arabinogalactan [SPIO-AG]) were injected into normal rats and rats with carbon tetrachloride-induced hepatitis. Before and after injection of either contrast agent, ex vivo relaxometry (0.94T) or in vivo MR imaging (1.0T) were performed. The obtained liver and tumor T1 and T2 relaxation times, liver and tumor signal-to-noise ratios (SNR), and tumor-liver contrast-to-noise ratios (CNR) of control rats and rats with hepatitis were compared. Both relaxometry and MR imaging showed that MnDPDP and SPIO-AG selectively enhanced liver tissue in controls and in rats with hepatitis to the same degree, and little tumor enhancement was seen in either group. As a result, no significant difference between control rats and rats with hepatitis was observed in the postcontrast tumor-liver CNR. For a MnDPDP-enhanced CNR with spin echo (SE) of 310/15, the results were -10.4±3.6 in control rats vs. -11.5±1.4 in rats with hepatitis; for a SPIO-AG-enhanced CNR with SE 2000/45 and 2000/90, respectively, the results were 30.7±9.2 and 18.7±4.7 in control rats vs. 31.9±7.1 and 17.7±2.4 in rats with hepatitis. These results indicate that hepatocyte-targeted contrast agents effectively enhance liver tissue and enhance liver-tumor image contrast despite hepatocellular dysfunction.

KW - Contrast media

KW - Hepatitis

KW - Iron

KW - Liver neoplasms

KW - Manganese

UR - http://www.scopus.com/inward/record.url?scp=33644876686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644876686&partnerID=8YFLogxK

U2 - 10.2463/mrms.4.53

DO - 10.2463/mrms.4.53

M3 - Article

C2 - 16340158

AN - SCOPUS:33644876686

VL - 4

SP - 53

EP - 60

JO - Magnetic Resonance in Medical Sciences

JF - Magnetic Resonance in Medical Sciences

SN - 1347-3182

IS - 2

ER -